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Abstract. Reinforcement Learning (RL) can be used to fit a mapping
from patient state to a medication regimen. Prior studies have used deter-
ministic and value-based tabular learning to learn a propofol dose from
an observed anesthetic state. Deep RL replaces the table with a deep
neural network and has been used to learn medication regimens from
registry databases. Here we perform the first application of deep RL to
closed-loop control of anesthetic dosing in a simulated environment. We
use the cross-entropy method to train a deep neural network to map an
observed anesthetic state to a probability of infusing a fixed propofol
dosage. During testing, we implement a deterministic policy that trans-
forms the probability of infusion to a continuous infusion rate. The model
is trained and tested on simulated pharmacokinetic/pharmacodynamic
models with randomized parameters to ensure robustness to patient vari-
ability. The deep RL agent significantly outperformed a proportional-
integral-derivative controller (median absolute performance error 1.7%
± 0.6 and 3.4% ± 1.2). Modeling continuous input variables instead of
a table affords more robust pattern recognition and utilizes our prior
domain knowledge. Deep RL learned a smooth policy with a natural
interpretation to data scientists and anesthesia care providers alike.
Keywords: anesthesia · reinforcement learning · deep learning
1 Introduction
The proliferation of anesthesia in the 1800s is America’s greatest contribution to
modern medicine and enabled far more complex, invasive, and humane surgical
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procedures. Now nearly 60,000 patients receive general anesthesia for surgery
daily in the United States [2]. Anesthesia is a reversible drug-induced state char-
acterized by a combination of amnesia, immobility, antinociception, and loss of
consciousness [2]. Anesthesia providers are not only responsible for a patient’s
depth of anesthesia, but also their physiologic stability and oxygen delivery.
Anesthesiologists need to determine the medication regimen a patient receives
throughout a surgical procedure. The anesthetic state is managed by providing
inhaled vapors or infusing intravenous medication. The medication most studied
for controlling the patient’s level of unconsciousness is propofol. Propofol affects
the brain’s cortex and arousal centers to induce loss of consciousness in a dose-
dependent manner. Propofol dosage needs to be balanced: patients should be
deep enough to avoid intraoperative awareness, but too much anesthesia can
cause physiologic instability or cognitive deficits. Currently anesthesiologists can
manually calculate and inject each dose, or select the desired concentration of
propofol in the brain, and an infusion pump will adjust infusion rates based on
how an average patient processes the medication.
Investigational devices and studies have shown that measuring brain activity
can provide personalized computer-calculated dosing regimens. Studies of au-
tomatic anesthetic administration have three primary components. First, sens-
ing involves automatically obtaining a numerical representation of the patient’s
anesthetic state. Prior studies have primarily focused on controlling the level of
unconsciousness (LoU) using a variety of indices, including the bispectral index
(BIS) [1, 5], WAVCNS [4], and burst suppression probability [15, 17]. Second,
modeling involves the development of pharmacokinetic (PK) and pharmacody-
namic (PD) models of how a patient’s LoU responds to specified drug dosages.
These models are used to derive optimal control laws [15], tune controller pa-
rameters [17], and/or develop robust controller parameterizations [4]. Finally, the
controller determines the mapping from sensed variables to drug infusion rates.
Numerous control algorithms have been studied for LoU regulation, including
(but not limited to) proportional integral derivative (PID) controllers, model pre-
dictive (MP) controllers, and linear quadratic regulator (LQR) controllers. The
performance of these algorithms is restricted by linearity assumptions and/or
reliance on a nominal patient model for obtaining the control action.
Reinforcement learning (RL) is a form of optimal control which learns by
optimizing a flexible reward system. RL can be used to fit a mapping from
anesthetic state to a propofol dose. Contrary to MP and LQR controllers, the
RL-based controllers can be model-free in that the control law is established
without any knowledge of the underlying model. Prior studies using tabular
RL created a table where each entry represents a discrete propofol dosage that
corresponds to a discrete observation [9–11]. Tabular mappings are flexible but
do not scale well with larger state spaces and can have non-smooth policies
that result from independently determining actions for each of the discretized
states. Continuous states have been used by actor-critic methods that use linear
function maps [8] and adaptive linear control [12]. Existing studies that train RL
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Fig. 1: Block diagram of the proposed RL framework.
agents to administer anesthesia tend to either underconstrain by disregarding
continuity or overconstrain by imposing strict linearity assumptions.
The use of deep neural networks as functional maps in RL (called “deep RL”)
has been used to learn medication regimens from registry databases outside of the
anesthesia context [7,13]. Existing deep RL studies use large observation spaces
and disregard known PK/PD properties. By using retrospectively collected data,
these studies do not permit the RL agent to learn from its own actions and
restrict the agent’s “teachable moments” to those that are observed in the data.
We perform the first application of deep RL to anesthetic dosing supported
with fundamental models from pharmacology. Using data from a simulated
PK/PD model, we implement an RL framework for training a neural network to
provide a mapping from a continuous valued observation vector to a distribution
over actions. The use of a deep neural network allows the number of parame-
ters of the model to scale linearly with the number of inputs to the policy map,
avoiding the exponential growth that occurs when expanding the input dimen-
sion of tabular policies. The resultant policy can represent nonlinear functions
while still yielding a smooth function of the input variables. By training the
RL agent on simulated data, we can control the range of patient models that
are included in the learning process. As such, the proposed framework allows
us to experiment with a variety of policy inputs in order to directly incorporate
robustness to patient variability into the training procedure.
2 Methods
In this section we develop a mathematical formalization for learning how to
administer propofol to control LoU. We formalize this propofol dosing task as a
partially observable Markov decision process (POMDP) and solve it using the RL
method cross-entropy. This RL “agent” learns from data generated by simulated
interactions with the environment PK/PD state-space model (see Figure 1).
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2.1 Environment Model
The primary component of the environment is the patient model, which dic-
tates the observed LoU given a drug infusion profile and is composed of three
sub-models. First, a discrete time 3-compartment pharmacokinetic (PK) model
is used to model the mass transfer of infused drug between the central, slow
peripheral, and rapid peripheral compartments:
xk+1 = Axk +Bak (1)
where xk = [x
(1)
k , x
(2)
k , x
(3)
k ] ∈ R3+ represents the 3-compartment model concen-
trations (where R+ represents the set of non-negative reals), ak ∈ A = {0, 1}
represents whether or not drug is infused at time k, A ∈ R3×3 gives the mass
transfer rates between compartments, and B = [∆u, 0, 0] represents the mass
transfer rate resulting from drug infusion. The parameters of A are determined
by the patient age, height, and weight according to the Schnider model [14]. In
the current study we have ∆ = 5 sec (as in [10]) and u = 1.67 mg/s, such that
over each five second window is either 0 mg or 8.35 mg of propofol is delivered.
The link function determines the effect site (i.e. brain) concentration from
the central compartment concentration:
x
(e)
k+1 = αx
(e)
k + βx
(1)
k (2)
where α = exp(−ke0∆/60) gives the persistence of drug in the effect site and
β = (ke0/60) exp(−ke0∆/60) gives the mass transfer rate from the plasma com-
partment to the effect site for a given plasma-brain equilibration constant ke0.
Finally, we compute how a given effect site concentration of propofol affects
LoU using a hill function:
yk = h(x
(e)
k ) =
x
(e)
k
γ
Cγ + x
(e)
k
γ (3)
where yk ∈ [0, 1] gives the true LoU at time k, C ∈ R+ give the effect site
concentration corresponding to a LoU of 0.5, and γ ∈ R+ determines the shape
of the non-linear PD response (higher values give rise to more rapid transitions
in LoU). Given that this PD model has been used in studies targeting control of
BIS [5], WAVCNS [4], and BSP [17], we choose to treat yk as a general index of
LoU in the present simulation study. As such, yk can be viewed as representing
a non-linear continuum from consciousness (0) to brain death (1). The clinical
interpretations of intermediate LoUs depend on the specific choice of index.
The observed LoU y˜k is obtained by adding Gaussian measurement noise
vk ∼ N (0, σ2v) to the true LoU yk. The resulting observed LoU is clipped to be
between zero and one. We set measurement noise at σ2v = 0.0003 [10].
2.2 Agent Model
At each timestep, the agent receives a measured LoU y˜k from the environ-
ment along with a target LoU y∗k and decides how much propofol to infuse.
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The agent uses these inputs and the infusion history to derive an observation
vector: ok = [o
(1)
k , . . . , o
(d)
k ] ∈ O = Rd. We use d = 4 with the following observed
variables: measured LoU error o
(1)
k = y˜k−y∗k, 30-seconds ahead predicted change
in effect site concentration o
(2)
k = xˆ
(e)
k+6−xˆ(e)k , 30-second historical change in mea-
sured LoU o
(3)
k = y˜k − y˜k−6, and the target LoU o(4)k = y∗k. The estimated effect
site concentration is computed by maintaining a PK model with generic param-
eterization (according to Table 1) throughout a trial to estimate concentration
levels xˆk and xˆ
(e)
k . At each time, this model is propagated 30 seconds forward
under the assumption that there will be no further infusion to yield xˆ
(e)
k+6, which
is used to compute the predicted change. All elements of the observation vector
can be computed solely from previous actions and measured LoUs, and they do
not assume any knowledge of the specific patient variables in the environment.
Each of the observation variables is presumed to provide the agent with a unique
advantage in selecting an action. For example, the predicted change in effect site
concentration is included to account for the lag between drug administration
and arrival at the effect site and including the target LoU enables the agent to
have different steady-state infusion rates for different target LoUs.
Sub-model Parameter Units Generic Minimum Maximum
PK Height cm 170 160 190
PK Weight kg 70 50 100
PK Age yr 30 18 90
Link ke0 min
−1 0.17 0.128 0.213
PD γ - 5 5 9
PD C - 2.5 2 6
Table 1: Model parameters for the generic patient and range of parameters se-
lected randomly for training and testing.
The agent uses a neural network to map observations to distributions over the
action space. This mapping, known as the policy, is represented by the function
pi(ak | ok), which assigns a probability to an action ak given an observation ok.
The network contains a single hidden layer with 128 nodes and ReLU activation
functions, with two output nodes passed through a softmax to obtain action
probabilities. The network is fully parameterized by the weights wpi ∈ R898
((4+1)×128+(128+1)×2 = 898, where the +1 accounts for a constant offset).
To promote exploration during training, the agent randomly selects an action
according to its policy. During testing, we employ three action selection modes.
In stochastic mode, the agent randomly selects an action according to its policy
as it does in training: a
(s)
k ∼ pi(· | ok). In deterministic mode, the agent selects
the action with the highest probability: a
(d)
k = argmax
a
pi(a | ok). In continuous
mode, the agent selects a continuous action corresponding to the policy’s prob-
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ability of infusing: a
(c)
k = pi(1 | ok). In all cases, the action yields a normalized
infusion rate that is multiplied by the maximum dose u in (1).
2.3 Cross-Entropy Training Algorithm
The agent’s policy network is trained using the cross-entropy method [3], an
importance sampling based algorithm that is popular in training deep reinforce-
ment learning agents [16]. The algorithm performs batches of simulations (re-
ferred to as episodes) and at the end of each batch updates the policy based
on the episodes where the agent performed best. The agent’s performance in a
given episode is assessed using a reward function.
For a given episode n in a collection of N episodes, we define the episode
reward to be the cumulative negative absolute error: rn =
∑K
k=1−|y∗n,k−yn,k| ∈
(−∞, 0], where K gives the fixed duration of an episode and y∗n,k and yn,k give
the target and true LoU at time k for episode n, respectively. After simulating
N episodes, the set Np of episodes in the pth percentile of rewards is identified,
and these are used to update the policy net parameters wpi. Letting an,k be the
action taken at time k in episode n and on,k be the corresponding observation
vector, define the cross-entropy loss for episode n as:
Ln = −
K∑
k=1
an,k log pi(an,k | on,k) + (1− an,k) log(1− pi(an,k | on,k)) (4)
Given that an,k is either zero or one, reducing the cross-entropy loss results in
nudging the policy pi to assign a higher probability to the action an,k when on,k is
observed. This nudge is accomplished by performing stochastic gradient descent
(SGD) on the policy net weights with the computed losses.
In our training, we used a cutoff of p = 70% (i.e. Np includes the best 30%)
and a batch size of N = 16. Between batches, we selected the patient parameters
randomly from a uniform distribution over the parameters specified in Table 1.
Four LoU targets y∗ were sampled uniformly from [0.25, 0.75], with each target
being used for 2,500 seconds before switching to the next, resulting in a total
episode duration of 10,000 seconds, or K = 2, 000. The patient parameters and
targets were kept fixed within a batch to avoid updating the policy based on
the “easiest” environments rather than on the best performance of the agent.
Further details on the training and reward system are provided in the Appendix.
2.4 PID Controller
Previous studies on RL-based control of propofol infusion tested control perfor-
mance against a PID controller [10]. The PID control action is determined by a
linear combination of the instantaneous error, the error integral, and the error
derivative. We use a discrete implementation of the PID controller:
a
(pid)
k = KP ek +KI
k∑
i=0
ek +KD
ek − ek−6
6
(5)
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Fig. 2: A: True and target LoU for typical/extreme cases for each controller.
B: State-subspace trajectory for typical/extreme cases for each controller. Each
point indicates a single step in a case’s trajectory. The normalized propofol
dosage administered at that step is indicated by color.
where KP , KI , and KD are the controller parameters and ek = y
∗
k − y˜k is the
error. The error derivative is approximated using a 30-second lag to avoid being
dominated by noise. To be consistent with the RL agent implementation, the
PID control action is normalized (a
(pid)
k ∈ [0, 1]) and multiplied by the maximum
infusion rate u in (1). To avoid reset windup during induction and target changes,
we implemented clamping on the integral term. The PID parameters were tuned
using the Ziegler and Nichols method [18] on simulations using the generic pa-
tient model (see Table 1), resulting in KP = 9, KI = 0.9, and KD = 22.5.
3 Results
Performance was evaluated on cases that had different patient demographics
and LoU targets. Figure 2A shows sample trajectories of the true and target
LoU for the cases with the worst, median, and best performance. The worst case
for each controller exhibits similar increases of oscillatory behavior, especially
pronounced at set-point escalations. Continuous RL used less propofol than PID
during induction (186 mg ± 57 and 210 mg ± 55) and throughout a whole case
(2430 mg ± 763 and 2457 mg ± 760), but more during maintenance (15 mg/min
± 5.6 and 14 mg/min ± 5.3). In the state-space view of these trajectories (Figure
2B), it is apparent that all trajectories involve a nearly linear decision threshold
with an intercept near the origin (o(1), o(2)) = (0, 0).
The controller performances were evaluated using the per-episode median ab-
solute performance error (MAPE) and median performance error (MPE), where
performance error is defined as PEk = 100
yk−y∗k
y∗k
. All RL test modes outper-
formed the PID controller (Figure 3A). Among the RL test modes, the contin-
uous action mode had the best performance. Notably, the continuous mode had
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Fig. 3: A: Median absolute performance error (MAPE) and median performance
error (MPE) across 1,000 test parameterizations for each of the four controllers.
B: Association between MAPE and PK/PD parameters for continuous action
mode. Each point represents a test-episode, positioned by that episode’s perfor-
mance and a PK/PD parameter. Overlaid blue lines represent linear trend.
a median (across episodes) MPE near zero, suggesting that the ability to select
continuous infusion rates helped reduce the controller’s bias. On the contrary,
the PID controller had nearly equivalent MAPE and MPE, suggesting that its
MAPE was limited by maintaining LoU at values slightly above the target. Ad-
justed 2-sided paired t-tests showed that all policies have significantly different
mean MPE and MAPE (p<0.05). The continuous RL controller was robust to
variation in patient age and height, but sensitive to differences in mass and PD
parameters, in particular to C (Figure 3B). While this initially seems to suggest
that our model performs better on patients with a higher drug requirements, it
is important to note that both γ and C affect the shape of the Hill function. As
such, for the range of γ indicated in Table 1, low C values correspond to steeper
PD responses than high C values. Sampling γ and C from a joint distribution
may reduce the apparent effect of C on performance. Finally, the continuous RL
controller had a duration out-of-bounds error (percentage of time at 5% or more
off target) of 6.0% as compared with 12.4% for the PID controller.
Figure 4 shows two-dimensional cross sections of the learned policy. We see
that the agent learns to transition sharply between the non-infusing and infusing
actions. While the decision boundary is essentially linear in the measured error
and predicted effect site concentration change, this boundary shifts to promote
more infusion when the LoU has been increasing to approach the target.
4 Discussion
Our experiments show that the proposed RL controllers significantly outperform
a PID controller. We attribute RL’s superior performance to the fact that its ob-
servation provides a much richer representation of the latent state of the system
under control than PID (which only observes the error). It is worth emphasizing
that we used a heuristic tuning method to optimize PID parameters on a generic
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Fig. 4: Policy maps show the policy net outputs (pi(1 | ok)) for three different 30
second LoU changes (o(3)) and a fixed target LoU (o(4)) of 0.5.
patient model, and it is possible that alternative tuning methods could improve
PID performance in our experiment. Nevertheless, such an extension would also
involve heuristics, and the ability to incorporate robustness considerations di-
rectly into the RL training paradigm yields a considerable benefit.
The behavior of the model can be interpreted by inspecting the policy. In
Figure 4 we see expected increases in propofol administration when the patient
is further below a target concentration and when the projected effect site concen-
tration is more rapidly falling. The tendency to administer more propofol when
the LoU has been rising may be related to behavior learned during set-point
transitions or an encoding of the patient sensitivity to a given dosage history of
propofol. Given that the agent’s internal generic patient model encodes the pre-
viously administered drugs, these policy maps suggest that the agent has learned
the interaction between change in LoU and predicted effect site concentration
change to determine at which error level drug should be administered.
The ideal way to test this algorithm would be conducting a closely monitored
prospective clinical trial. Reinforcement learning algorithms are notoriously dif-
ficult to evaluate. Usually there is not an opportunity to collect prospective
data according to the agent’s policy, and policies are instead evaluated on ret-
rospective data collected according to a different policy [6]. In this study we
changed the propofol dosage exactly every 5 seconds, whereas in standard prac-
tice dosages are changed sporadically with individual infusion rates lasting min-
utes to hours. Reasonable approaches to evaluating this algorithm prospectively
include non-human studies with standard dose-safety limits or clinically with a
human-in-the-loop study where the agent acts as a recommender system.
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Appendix
The algorithm described in Section 2.3 is provided in detail in Algorithm 1.
Training will terminate once either a maximum number of batches imax is exe-
cuted or the desired batch reward r¯min is obtained.
Algorithm 1: Cross-entropy Training
Input: p, N ,imax,r¯min
Output: pi : O → A
1 randomly initialize policy net weights wpi ;
2 set i = 0, r¯ = −∞;
3 while i < imax and r¯ < r¯min do
4 sample model parameters and targets;
5 simulate N episodes and compute rewards {rn}n=1,...,N ;
6 select episodes with top p percentile of rewards;
7 compute cross-entropy loss between actions performed in the top episodes
and associated policy net outputs pi(a|s);
8 perform stochastic gradient descent step to reduce the cross-entropy loss
with respect to the policy net parameters wpi;
9 set i = i+ 1, r¯ = 1
N
∑
n rn;
10 end
The per-batch mean reward r¯ and policy network loss L associated with
the training of our model are shown in Figure 5, where the policy network
loss is found by summing the loss over the best performing cases in the batch:
L = ∑n∈Np Ln . We set the maximum number of iterations to 4,000 and visu-
ally confirmed that both the reward and loss converged. Given that the reward is
represented as the negative of an absolute value, the maximum possible reward
is zero, which is obtained only when the true LoU exactly matches the target
LoU for the entirety of a case. Due to the inherent limitations of the environ-
ment model (for example the delay between infusion and change in effect site
concentration), we expect some non-negligible error to occur at induction and
target change points.
Fig. 5: Round mean reward and policy network loss for each batch (corresponding
to the iteration index i in Algorithm 1).
